Fig. 1From: CA19-9 in combination with P-CRP as a predictive marker of immune-related adverse events in patients with recurrent or unresectable advanced gastric cancer treated with nivolumabCONSORT diagram CONSORT, Consolidated Standards of Reporting TrialsBack to article page